AnaptysBio, Inc.

Stage 3 · Topping · week 6

As of Oct 22, 2026, AnaptysBio is in Stage 3, the topping phase, now in week 6 (since Sep 14, 2026). It closed at $48.10, 31.1% below its 52-week high and below its 200-day average, which is rising.

AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States. More about the company

$48.10

+0.33% today

$1.4B · Small cap

Market Neutral — Building

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is ANAB early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 14w

S2 19w

S4 15w

S1 15w

S2 41w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 1w → S1 4w → S4 14w → S1 4w → S2 10w → S3 8w → S2 19w → S3 7w → S4 15w → S1 15w → S2 8w → S3 7w → S2 41w → S3 4w → S2 3w → S3 6w current

Total tracked: 165 weeks across 16 stage runs.

ANAB among Biotechnology40th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…40	ANABAnaptysBio, Inc.	Stage 3 · wk 6	95	−5.3%

vs 52W High

-31.1%

$22.06 lo$69.81 hi

31.1% below 52W high, weakening from peak

The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.

Stage Maturity

Week 6

1w13w26w

Week 6, distribution

How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.

vs 200 DMA

-3.5%

200 DMA: $49.87 · rising

Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.

Rel Volume

0.49x

vs 50-day avg

Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-5.3%

-11.2%

-6.2%

YTD

+60.5%

+111.5%

Scan Membership

Breakout Watch

Latest: 2024-06-07

8 appearances in last 60 days. First seen: 2020-07-08.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S3

Wk 6 · Vol 0.49x

2026-10-21S3

Wk 6 · Vol 1.15x

2026-10-20S3

Wk 6 · Vol 2.44x

2026-10-19S3

Wk 6 · Vol 0.94x

2026-10-16S3

Wk 5 · Vol 0.84x

2026-10-15S3

Wk 5 · Vol 0.85x

2026-10-14S3

Wk 5 · Vol 1.01x

2026-10-13S3

Wk 5 · Vol 0.85x

2026-10-12S3

Wk 5 · Vol 0.75x

2026-10-09S3

Wk 4 · Vol 0.98x

2026-10-08S3

Wk 4 · Vol 1.11x

2026-10-07S3

Wk 4 · Vol 1.54x

Moving averages & range

50 DMA

$52.85

200 DMA

$49.87

52W High

$69.81

52W Low

$22.06

5D Low

$45.43

Resistance levels (recent highs)

20d High

$51.00

60d High

$59.69

120d High

$69.81

250d High

$69.81

Next resistance

+6.0%

to 20d High

Dividend Yield

0.00%

P/B 135.1

AnaptysBio: quick answers

What stage is AnaptysBio in?

As of Oct 22, 2026, AnaptysBio (ANAB) is in Stage 3, the topping phase. It entered Stage 3 on Sep 14, 2026 and is in week 6. What the four stages mean

Is AnaptysBio in an uptrend?

Its uptrend has stalled. AnaptysBio is in Stage 3, the topping phase that follows an advance. It trades 3.5% below its 200-day average, which is rising.

How far is AnaptysBio from its 52-week high?

AnaptysBio closed at $48.10 on Oct 22, 2026, 31.1% below its 52-week high of $69.81. Its 52-week low is $22.06.

How has AnaptysBio performed over the past year?

As of Oct 22, 2026, AnaptysBio is up 111.5% over the past year and up 60.5% so far in 2026.

Which sector and industry is AnaptysBio in?

AnaptysBio is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States. The company manages financial collaborations for Jemperli, a PD-1 antagonist for various solid tumor indications; and Quimilza, an IL-36R antagonist mAb, which has completed two registration-enabling global Phase 3 trials, and GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of Quimilza in patients with generalized pustular psoriasis. It has a collaboration and exclusive license agreement with GSK plc to develop Jemperli as a monotherapy; and an exclusive license agreement with Vanda Pharmaceuticals Inc. for the development and commercialization of Quimilza. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.